Histone deacetylases (HDACs) are a class of zincdependent metalloproteinases that catalyze the removal of acetyl groups from lysine residues on histones and non-histone proteins. This action results in a "closed" chromatin configuration, thereby regulating the expression of genes, which include tumor suppressor genes (1, 2) . HDAC inhibitors (HDACIs) have attracted a great deal of interest as anticancer drug agents. Over the past 10 years, over 490 clinical trials of more than 20 HDACI candidates as anticancer agents have been conducted. Three HAACIs, vorinostat (SAHA, Zolinza ® ), romidepsin (FK-228, Istodax ® ), and belinostat (PXD101, Beleodaq ® ) have been approved for the treatment of hematologic tumors. In clinical use as anti-cancer agents (such as vorinostat, panobinostat, belinostat, and abexinostat), many HDACIs inhibit a broad spectrum of HDACs, including Class Ι , II, and IV isoforms. Although these HDACIs have promising efficacy in treating specific tumors, they all exhibit significant toxicity, including fatigue, nausea, vomiting, thrombocytopenia, and neutropenia (3). Thus, increased effort is being directed toward developing HDACIs that selectively inhibit certain classes or a single isoform. This should result in agents that are tolerated better and cause fewer adverse reactions. Several selective Class I, class IIa, and HDAC6 inhibitors ( Figure 1 ) have been reported, but only a few selective Class I inhibitors are used clinically (4-7). Selective HDAC6 inhibitors are expected to be benefi cial since they may cause fewer adverse reactions. However, the literature indicates that such small molecules have not played a prominent role in cancer therapy, with the exception of their combination with other chemotherapeutics (8) . Selective Class I HDACIs such as MS-275 and MGCD0103 (HDAC1, 2, and 3-selective) are the most studied selective HDACIs in clinical use or in development. However, these therapeutic have been found to have similar toxicity profiles and overall tolerability in comparison to pan-HDACIs (9) . A reasonable explanation for this is that selective Class I HDACIs in clinical use may not be selective enough to offer a superior therapeutic benefi t over pan-inhibitors. Given this fact, several improved selective inhibitors have been described (Figure 2 ). These inhibitors have better potency and selectivity for HDAC1 and 2 versus HDAC3 (10, 11 manner. An In vivo study in a subcutaneous U937 xenograft model revealed that the most potent and selective compound was 11r, which inhibited tumor growth 55.1% (Table 2) . Moreover, mice treated with 11r had no signifi cant weight loss and no signs of liver or spleen toxicity (12) . More detailed study of their mechanism of anticancer activity and optimization of their structure to improve transcellular permeability and isoform selectivity are underway in this laboratory. Selective HDAC1/3 inhibitors are selective for HDAC1 and 3 versus HDAC2, so this type of selective inhibitor may offer a better therapeutic approach over pan-HDACIs. In addition to their activity against cancer, HDACIs have been studied in the treatment of neurodegenerative disorders, including Huntington's disease and Friedreich's ataxia. Thus far, a phase Ι clinical study of selective Class ΙHDACI RG2833 for the treatment of Friedreich's ataxia has begun, and phase II clinical trials of selective SIRT 1 inhibitors to treat Huntington's disease (HD) have been conducted. Moreover, HDACIs, and particularly hydroxamatebased inhibitors, have surprisingly been found to show synergistic activity with antifungal agents against fungal species at concentrations that are not toxic to the host. One example is HDACI MGCD290, which was discovered by MethyGene. This inhibitor has been found to have activity against fungal pathogens (including azole-resistant yeasts) especially when used in combination with azole antifungals (13) . Human HDACs are related to yeast transcriptional regulators and have similar sequences to yeast Rpd3, Hda1, and Sir2, so an interesting question is whether selective HDACIs have the potential to exhibit such antifungal activity. The anticancer activity of selective HDAC1/3 inhibitors has been verifi ed, but their potential use in other ways, such as treatment of neurodegenerative disorders and fungal infection, has yet to be explored. Thus, HDACIs need to be studied a great deal more. 
